

Germany's Exyte Empowers the Biopharmaceutical Industry in China

30 July 2021 | News

First ExyCell(R) facility launched in Shanghai to develop an innovative, sustainable, and cost-effective facility for cell therapy manufacturing



Exyte has successfully completed the construction of the first ExyCell® facility in China, the CliniMACS Cell Factory® of Miltenyi Biotec, a global provider of integrated solutions for Advanced Therapy Medical Products (ATMPs).

The patented ExyCell technology was developed by Exyte as an end-to-end, integrated facility solution with standardized and modularized elements. These pre-configured and pre-fabricated modules enable fast-track construction thereby shortening time-to-market for new therapeutics and vaccines. Miltenyi Biotec is transferring production technology from Germany to China with regular operations for ATMP production is expected by autumn 2021.

Exyte and Miltenyi Biotec have developed an innovative, sustainable, and cost-effective facility for cell therapy manufacturing. This facility combines the CliniMACS Cell Factory manufacturing platform with the pre-fabricated ExyCell module enabling fast deployment of small, medium, and large scale cell manufacturing facilities based on a flexible cell therapy manufacturing module.

Dr. Boris Stoffel, Member of the Management Board of Miltenyi Biotec, emphasized the importance of this partnership: "As a company, we want to enable our customers in their efforts to make innovative cell and gene therapies available to patients worldwide. We believe that combining the proven CliniMACS Cell Factory manufacturing platform with the pre-fabricated ExyCell module will help fast-tracking new therapies to the benefit of global healthcare."

The effective combination of the CliniMACS Cell Factory ballroom concept built into the ExyCell module allows the flexibility to build, scale-up, expand, or repurpose a facility with minimal impact to ongoing production operations. The ExyCell platform can either be purchased in its standard version or adapted to specific needs of production capacity, cleanroom size, control systems, and finishing options.